Advertisement
Research Article

Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu–Natal, South Africa

  • Karen I Barnes mail,

    To whom correspondence should be addressed. E-mail: kbarnes@uctgsh1.uct.ac.za

    Affiliation: Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa

    X
  • David N Durrheim,

    Affiliation: Health Protection, Hunter New England Population Health, Newcastle, New South Wales, Australia

    X
  • Francesca Little,

    Affiliations: Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa, Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa

    X
  • Amanda Jackson,

    Affiliation: Malaria Research Lead Programme, Medical Research Council, Durban, South Africa

    X
  • Ushma Mehta,

    Affiliation: Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa

    X
  • Elizabeth Allen,

    Affiliation: Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa

    X
  • Sicelo S Dlamini,

    Affiliation: Malaria Research Lead Programme, Medical Research Council, Durban, South Africa

    X
  • Joyce Tsoka,

    Affiliation: Malaria Research Lead Programme, Medical Research Council, Durban, South Africa

    X
  • Barry Bredenkamp,

    Affiliation: Malaria Research Lead Programme, Medical Research Council, Durban, South Africa

    X
  • D. Jotham Mthembu,

    Affiliation: Malaria Control Programme, KwaZulu–Natal Provincial Department of Health, South Africa

    X
  • Nicholas J White,

    Affiliations: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Centre of Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

    X
  • Brian L Sharp

    Affiliation: Malaria Research Lead Programme, Medical Research Council, Durban, South Africa

    X
  • Published: October 04, 2005
  • DOI: 10.1371/journal.pmed.0020330

About the Authors

Karen I Barnes, Francesca Little, Ushma Mehta, Elizabeth Allen
Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
David N Durrheim
Health Protection, Hunter New England Population Health, Newcastle, New South Wales, Australia
Francesca Little
Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa
Amanda Jackson, Sicelo S Dlamini, Joyce Tsoka, Barry Bredenkamp, Brian L Sharp
Malaria Research Lead Programme, Medical Research Council, Durban, South Africa
D. Jotham Mthembu
Malaria Control Programme, KwaZulu–Natal Provincial Department of Health, South Africa
Nicholas J White
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Nicholas J White
Centre of Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

Corresponding Author

Email: kbarnes@uctgsh1.uct.ac.za

Competing Interests

NJW is chairman of the World Health Organization malaria treatment guidelines committee and is on the editorial board of PLoS medicine. The authors have no other conflict of interest to declare.

Author Contributions

KIB is the principal investigator of the South East African Combination Antimalarial Therapy (SEACAT) evaluation, within which this study was nested. KIB conceptualised this study and analysed the data, drafted this manuscript, and together with DND, NJW, and BLS designed and interpreted results of all study components. FL supervised the statistical analyses performed. AJ managed data entry and together with SSD conducted preliminary analysis and interpretation of the household survey. UM conducted preliminary analysis and interpretation of sentinel safety data. JT conducted preliminary analysis and interpretation of sentinel hospital morbidity and mortality data. EA and BB assisted in the design, and together with DJM, assisted in the coordination of the in vivo study. All authors revised manuscript critically for substantial intellectual content and have access to all data in the studies reported.